Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics (CH:HTD)
:HTD
HTD Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Business Model StrengthThe feedback has been overwhelmingly positive and the company's business model is as strong as ever.
Clinical Trial SuccessRelacorilant demonstrates strong efficacy in PARPi exposed PROC patients.
Regulatory ApprovalAnalyst remains confident that relacorilant is likely to receive the FDA approval for the treatment of platinum-resistant ovarian cancer.
Bears Say
Distribution ChallengesThe departure of Optime Care as a distributor of Korlym causes a delay in Corcept's strategy to have two pharmacies operational, which may lead to near-term sales headwinds.
Sales ProjectionsThe company is lowering its sales projections for Korlym due to the disruption in distribution, with a reduction in 2025 sales estimates.
Corcept Therapeutics News
HTD FAQ
What was Corcept Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Corcept Therapeutics’s market cap?
Currently, no data Available
When is Corcept Therapeutics’s upcoming earnings report date?
Corcept Therapeutics’s upcoming earnings report date is Feb 18, 2026 which is in 104 days.
How were Corcept Therapeutics’s earnings last quarter?
Corcept Therapeutics released its earnings results on Nov 04, 2025. The company reported $0.129 earnings per share for the quarter, missing the consensus estimate of $0.133 by -$0.003.
Is Corcept Therapeutics overvalued?
According to Wall Street analysts Corcept Therapeutics’s price is currently Undervalued.
Does Corcept Therapeutics pay dividends?
Corcept Therapeutics does not currently pay dividends.
What is Corcept Therapeutics’s EPS estimate?
Corcept Therapeutics’s EPS estimate is 0.27.
How many shares outstanding does Corcept Therapeutics have?
Currently, no data Available
What happened to Corcept Therapeutics’s price movement after its last earnings report?
Corcept Therapeutics reported an EPS of $0.129 in its last earnings report, missing expectations of $0.133. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Corcept Therapeutics?
Currently, no hedge funds are holding shares in CH:HTD
Company Description
Corcept Therapeutics
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
HTD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and a robust pipeline, particularly in hypercortisolism and oncology. However, challenges such as a significant decline in net income and unresolved patent litigation present concerns.View all CH:HTD earnings summariesJazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
Legend Biotech
―
Options Prices
Currently, No data available
---